KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Expenses (2017 - 2025)

Regeneron Pharmaceuticals has reported Accumulated Expenses over the past 12 years, most recently at $2.9 billion for Q4 2025.

  • Quarterly results put Accumulated Expenses at $2.9 billion for Q4 2025, up 13.82% from a year ago — trailing twelve months through Dec 2025 was $2.9 billion (up 13.82% YoY), and the annual figure for FY2025 was $2.9 billion, up 13.82%.
  • Accumulated Expenses for Q4 2025 was $2.9 billion at Regeneron Pharmaceuticals, down from $3.0 billion in the prior quarter.
  • Over the last five years, Accumulated Expenses for REGN hit a ceiling of $3.0 billion in Q3 2025 and a floor of $1.5 billion in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $2.2 billion (2021), compared with a mean of $2.3 billion.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 60.54% in 2021 and later dropped 12.84% in 2022.
  • Regeneron Pharmaceuticals' Accumulated Expenses stood at $2.2 billion in 2021, then fell by 6.01% to $2.1 billion in 2022, then grew by 13.68% to $2.4 billion in 2023, then grew by 7.18% to $2.5 billion in 2024, then rose by 13.82% to $2.9 billion in 2025.
  • The last three reported values for Accumulated Expenses were $2.9 billion (Q4 2025), $3.0 billion (Q3 2025), and $2.5 billion (Q2 2025) per Business Quant data.